Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial

This study was conducted to demonstrate the efficacy and safety of LixiLan (iGlarLixi), a novel, titratable, fixed-ratio combination of insulin glargine (iGlar) (100 units) and lixisenatide, compared with iGlar in patients with type 2 diabetes inadequately controlled on basal insulin with or without...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes care 2016-11, Vol.39 (11), p.1972-1980
Hauptverfasser:	Aroda, Vanita R, Rosenstock, Julio, Wysham, Carol, Unger, Jeffrey, Bellido, Diego, González-Gálvez, Guillermo, Takami, Akane, Guo, Hailing, Niemoeller, Elisabeth, Souhami, Elisabeth, Bergenstal, Richard M
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Blood Glucose - metabolism Body Mass Index Body Weight Clinical trials Diabetes Diabetes Mellitus, Type 2 - drug therapy Dose-Response Relationship, Drug Drug Combinations Drug Evaluation, Preclinical Endpoint Determination Female Glycated Hemoglobin A - metabolism Humans Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - therapeutic use Insulin Insulin - therapeutic use Insulin Glargine - administration & dosage Insulin Glargine - therapeutic use Male Medical treatment Metformin - therapeutic use Middle Aged Peptides - administration & dosage Peptides - therapeutic use Pharmaceuticals Side effects Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!